Cationic Nanoparticle Solubilization of Lyophilized Antigens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for solubilizing lyophilized proteins for vaccine compositions require the use of lyophilization aids, which can have undesirable effects and are not compatible with vaccine administration, leading to instability and the need for frequent production of antigen stocks.
Innovation Solution
A method using cationic nanoparticles with a cationic polysaccharide core to solubilize lyophilized antigens in an aqueous medium without the need for additional solubilization aids, allowing for rapid preparation of vaccine compositions that are stable and flexible for use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If lyophilization aids (such as albumin, arginine, histidine, saccharose, mannitol) are used to solubilize lyophilized antigens, then solubilization is achieved, but the composition contains undesirable additives that are not compatible with vaccine administration
Solution Approach 1:
The invention extracts and eliminates the need for lyophilization aids from the vaccine composition process. By using cationic nanoparticles that can directly solubilize lyophilized antigens without requiring albumin, arginine, histidine, saccharose, or mannitol, the harmful additives are completely removed from the final vaccine formulation while maintaining effective solubilization.
Solution Approach 2:
Cationic nanoparticles serve as an intermediary substance that enables solubilization of lyophilized antigens without introducing harmful additives into the vaccine composition. The nanoparticles act as a bridge between the lyophilized antigen and the aqueous vaccine medium, facilitating solubilization through electrostatic interactions while remaining compatible with vaccine administration.
2Ease of operation
If conventional solubilization methods are used, then antigens can be dissolved, but the composition requires frequent production of antigen stocks due to instability
Solution Approach 1:
The invention changes the physical and chemical parameters of the solubilization process by using cationic nanoparticles with specific charge characteristics. This parameter change enables the formation of stable antigen-nanoparticle complexes that maintain compositional stability over time, eliminating the need for frequent production of antigen stocks while simplifying preparation procedures.
3Ease of operation
If lyophilization aids are added to solubilize antigens, then solubilization is achieved, but the process requires additional substances that increase complexity
Solution Approach 1:
The invention extracts the unnecessary complexity of multiple lyophilization aids from the vaccine formulation process. By using only cationic nanoparticles for solubilization, the formulation is simplified to contain only the essential active ingredients without albumin, arginine, histidine, saccharose, or mannitol, thereby reducing formulation complexity while maintaining ease of operation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables rapid and stable solubilization of lyophilized antigens, preventing the use of undesirable additives, enhancing antigen presentation, and allowing for the combination of different antigens to create adjustable vaccines, reducing production costs and improving stock management.
Implementation Method 1
solubilizing the lyophilized antigen in the aqueous solution comprising a cationic nanoparticle
Data Source
AI summary
The field of extemporaneous preparation of vaccine compositions from lyophilized antigens. More specifically, the present disclosure relates to the use of cationic nanoparticles to render the lyophilized antigens more soluble without adding a lyophilization aid, with a view to extemporaneous use for administering a vaccine composition. In a particular embodiment, the present disclosure allows a vaccine formulation to be prepared or one or more valencies to be added to a previously formulated vaccine composition.